News Focus
News Focus
icon url

Snowy_Owl

04/20/18 6:56 AM

#225224 RE: Amatuer17 #225219

Tell us when the trial was unblinded and how long it should take to analyze the data. You've repeatedly issued proclamations that it's taking too long so enlighten us. How long should it take and when did the data become available?

These CROs are big and have very large capacity to handle multiple trials. P trial had only 199 patients.
In most cases the data is entered into the tool by sites directly as they have advance tools

icon url

BooDog

04/20/18 7:33 AM

#225226 RE: Amatuer17 #225219

Future expectations can not be based on past results. That's really what you're saying. Not that it's a bad way of thinking. The flaw is not taking into account past results at all and simply surmising that results must be bad because it has been taking so long to get the results. 80% failure huh? I can tell you that I have also decided not to ride certain bio's into data and have been left in the dust because of that decision. To date prurisol has met/exceeded endpoints. I give data a 60+% chance of success.
Is the pps a reflection of pricing in a failure? Quite possibly. Who's going to be right? I suspect we'll find out very soon. The catalysts for brilacidin alone bring this right back up, and then some imo.

Message in reply to:

These CROs are big and have very large capacity to handle multiple trials. P trial had only 199 patients.
In most cases the data is entered into the tool by sites directly as they have advance tools

The trial had 2 PE and 9 SE - only 1 PE and 4 SE depended on 16 week data. So by the time last patient visit on Dec 21st - most of the 12 week and 16 week data was already collected and available with CRO - and most likely entered into DB.

So the time taken for even giving primary outcome and say whether it met or not is suspiciously long.

Typically most of them issue PE results soon and if good/great, keep secondary and detailed results for scientific conf

In biotech - in my experience -
No news in 80% of the cases is bad news

Simply because tiny biotechs live on positive news cycle and die based on delayed or bad news

It clearly seems to me that P results are not going to be that great and Leo is trying to time it with some alternate news to reduce the blow.

But hey - this is already 40 cent share - it could soon become 10 cent



Go $IPIX